NIH Licenses Heart-Defective Super Mice for Research Breakthroughs
Published Date: 10/2/2025
Notice
Summary
The National Institutes of Health has created new mouse models that help scientists study heart problems linked to the Casq2 gene. These special mice can turn certain genes off in a controlled way, speeding up research and drug development. Researchers and biotech companies can now license this technology to boost their work, with no immediate costs but big potential for future breakthroughs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Licensing Available for Casq2 Mouse Models
The National Institute of Child Health and Human Development (NICHD) at the NIH created special mouse models that let scientists turn off the Casq2 gene in a controlled way to study heart problems. These government-owned inventions are available for licensing to researchers and biotech companies to help speed research and commercialization, and the notice says there are no immediate costs to license while offering potential for future breakthroughs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-19374, Arms Sales Notification
The Department of Defense just announced new arms sales to friendly countries, sharing details on what’s being sold and when. This update affects international partners and signals upcoming changes in military gear and budgets. Keep an eye out for these deals—they show how the U.S. supports allies while managing big-dollar defense moves.
Next: 2025-19376, Government Owned Inventions Available for Licensing and/or Collaboration: Acyloxyacyl Hydrolase (AOAH) and Methods of Use as a Cancer Immunotherapy
The National Cancer Institute has a cool new invention called Acyloxyacyl Hydrolase (AOAH) that could help fight cancer by boosting the immune system. This invention is ready for companies or researchers to license or team up on, speeding up the journey from lab to real-life treatments. If you’re in biotech or cancer research, now’s the time to jump in and make a difference!